Jump to content
Powered by

Selected press releases

  • Press release - 28/09/2022

    Screening trials for the early detection of rare diseases often fail due to insufficient predictive power of the results. For the rare HPV-related cancer of the pharynx, scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) now relied on the combined detection of antibodies against two different viral proteins in a proof-of concept trial.

  • Press release - 27/09/2022

    Innovative engineering approaches to research and teaching are at the core of the Faculty of Engineering Sciences, which Heidelberg University founded with the aim of pooling its technical and scientific expertise and expanding its range of research and subjects in an area of competence that is developing dynamically.

  • Press release - 21/09/2022

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

  • Press release - 19/09/2022

    Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis.

  • Press release - 09/09/2022

    Cancer cells often grow in environments that are low in nutrients, and they cope with this challenge by switching their metabolism to using proteins as alternative "food". Building on genetic screens, an international team of scientists could identify the protein LYSET as part of a pathway that allows cancer cells to make this switch. Their findings are now published in the journal Science.

  • Press release - 06/09/2022

    Today, genome editing is almost as easy as programming software. However, the generation of viral vectors as initial material is still associated with many expensive and error-prone handling procedures. Viruses are generated via complex biological processes that have to be optimised virus-specifically in order to produce high-quality therapeutics. A new method is needed that simplifies and optimises these processes.

  • Press release - 01/09/2022

    Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

  • Press release - 31/08/2022

    Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.

  • Press release - 18/08/2022

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on mRNA, today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.

  • Press release - 18/08/2022

    University of Tübingen team discovers how malformations of the blood vessels can occur in mice – yielding information with possible ramifications for retinal disease.

  • Press release - 04/08/2022

    In mice, inflammation in early to mid-life leads to a permanent decline in functional blood stem cells, according to a recent publication by scientists from the German Cancer Research Center (DKFZ) and the Stem Cell Institute HI-STEM*. The ability of the blood stem cells to regenerate was suppressed for at least one year after challenge with inflammation.

  • Press release - 29/07/2022

    A centre for model-based artificial intelligence has been set up at Heidelberg University to link mathematical modelling methods with information processing in neuronal networks. The Carl Zeiss Foundation (CZS) is funding the CZS Heidelberg Center for Model-Based AI with five million euros over a period of six years.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release